Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor

EU Rights Acquisition:
Leo Pharma has secured the rights to promote and sell Loqtorzi (toripalimab), a PD-1 inhibitor, in the European Union from Shanghai Junshi Biosciences2 4.

Indications:
Loqtorzi is indicated for the first-line treatment of nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine, and as a monotherapy for recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy1 3.

Clinical Efficacy:
Loqtorzi has demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in clinical trials. It reduced the risk of disease progression or death by 48% and the risk of death by 37% compared to chemotherapy alone1 3.

Mechanism of Action:
Loqtorzi is an anti-PD-1 humanized IgG4 monoclonal antibody that blocks the interaction between PD-1 and its ligands, enhancing the immune response against tumor cells1 3.

Future Developments:
Loqtorzi is also being explored for other indications, including advanced hepatocellular carcinoma (HCC), where it has shown promising results in a Phase III study5.